RE:Anyone have any ideasVentripoint Diagnostics Ltd. (V.VRS)
Basically they define in space specific points on a 2D ultrasound image of a heart to reconstruct a mosaic virtual 3D image from a database that contains images and data from all heart shapes both normal and in various stages of disease. This reconstructed image closely resembles the actual heart in both shape and condition. As a diagnostic tool it rivals in accuracy the results obtained by an MRI, which is the Gold Standard. I have been in this stock since early last year and am now reaping the first rewards. Points of interest as to why I own Ventripoint:
- Fast (15 minutes)
- Convenient (can be achieved in a single visit)
- Cost effective (compared to MRI or CT)
- Safe (no radiation)
- Uses existing 2D ultrasound equipment
- Accurate (to gold-standard MRI)
- Easy to learn and use by sonographers and physicians
- Low capital cost (compared to MRI, CT or 3D echo)
- Works on virtually everyone (high feasibility)
- Easy to standardize between operators and hospitals
- Generates 4-page report with all functional and QC data as well as 3D images of the heart
- Generates patient history for heart analysis and plots trends
- Analysis available at remote workstation
- Cloud-computing implementation for remote problem solving and software updates
- Verified by independent clinical studies to be as accurate as MRI and better than 3D-echo
- Increases MRI productivity by off-loading cardiac MRI patients and freeing up MRI for other cases
- Shortens waitlist times for cardiac patients requiring routine heart check ups
- Quickly closing of all capital raises, in some cases with oversubscriptions.
- They not only exhibit at conferences, but third party researchers present as keynote speakers in support of Ventripoint 3D.
- Have drawn interest of major players in the ultrasound business, and have co-exhibited with Toshiba.
- Up to $70,000 per year per device sold in reoccurring revenue.
- They are a software company that has stated they have no interest in building and selling ultrasound hardware, and will be seeking buyout.
- Have Canadian and European Approvals.
- Second time around for FDA Approval. Required more validation data, which has been completed and submitted.
- Frugal company - has issued shares for services rendered at above trading price at time of issue.
- They are not 28 million in debt, unlike our beloved Mint.
- Behind in their schedule, which is not uncommon for biotechs in their position, however they are cashed up and are waiting for a response from FDA.
Ventripoint is currently "up at bat" in my line up of stocks waiting to swing. What has everybody else got that looks promising and could make up for the disaster we have here?
If you are out there MT, I am sure the board would be interested in your best pick.